title: Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
abstract: An investigational tetravalent combined measles, mumps, rubella, and varicella vaccine and measles-mumps-rubella and varicella vaccines at separate injection sites given at the same visit were evaluated with respect to safety and cell-mediated and humoral immune responses at 6 weeks and 1 year after vaccination. Varicella seroconversion rates and lymphocyte proliferation responses were 100% for both vaccine groups at 6 weeks and 1 year. However, the antibody titer to varicella was lower in the combined vaccine group at 6 weeks, but there was no statistical difference in cell-mediated immune responses. One-year geometric mean titers were not statistically different. Seroconversion rates for measles, mumps, and rubella were 100% for both vaccine at 6 weeks and 1 year. Long-term follow-up of these immune responses is planned.
authors.affiliation: Division of Allergy, Immunology and Infectious Diseases, Children's Hospital of Philadelphia, PA 19104, USA.
authors.forename: B M
authors.initials: BM
authors.lastname: Watson
authors.forename: D S
authors.initials: DS
authors.lastname: Laufer
authors.forename: B J
authors.initials: BJ
authors.lastname: Kuter
authors.forename: B
authors.initials: B
authors.lastname: Staehle
authors.forename: C J
authors.initials: CJ
authors.lastname: White
authors.forename: S E
authors.initials: SE
authors.lastname: Starr
mesh_terms: D000914:Antibodies, Viral / Q000097:blood; D019433:Chickenpox Vaccine; D005260:Female; D014645:Herpesvirus 3, Human / Q000276:immunology; D006801:Humans; D066298:In Vitro Techniques; D007223:Infant; D008213:Lymphocyte Activation; D008297:Male; D008458:Measles Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D008459:Measles virus / Q000276:immunology; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D009109:Mumps virus / Q000276:immunology; D012411:Rubella Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D012412:Rubella virus / Q000276:immunology; D012449:Safety; D017778:Vaccines, Combined / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D019433:Chickenpox Vaccine; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine; D017778:Vaccines, Combined; D014765:Viral Vaccines